Palbociclib in Estrogen Receptor Positive (ER+) Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: HER2-positive Breast Cancer|Breast Cancer Metastatic
Interventions: DRUG: Palbociclib 75mg|DRUG: Letrozole 2.5mg|DRUG: T-DM1|DRUG: Palbociclib 100mg|DRUG: Palbociclib 125mg|DRUG: Palbociclib
Sponsor: University of Kansas Medical Center
Collaborators: Pfizer